These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26077641)

  • 1. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
    Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
    Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast.
    Barnes NL; Dimopoulos N; Williams KE; Howe M; Bundred NJ
    Eur J Surg Oncol; 2014 Mar; 40(3):249-54. PubMed ID: 24433818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast: literature review and single-centre retrospective series.
    Koh VCY; Lim JCT; Thike AA; Cheok PY; Thu MMM; Li H; Tan VKM; Ong KW; Tan BKT; Ho GH; Thilagaratnam S; Wong JSL; Wong FY; Ellis IO; Tan PH
    Histopathology; 2019 Jun; 74(7):970-987. PubMed ID: 30734334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
    Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
    Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; de Vries J; Wesseling J; de Bock GH
    Ann Surg Oncol; 2007 Jul; 14(7):2097-104. PubMed ID: 17453296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease?
    Evans AJ; Pinder SE; Ellis IO; Wilson AR
    J Med Screen; 2001; 8(3):149-51. PubMed ID: 11678555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of breast cancer through population-based mammographic screening in Asian women: a comparison study between screen-detected and symptomatic breast cancers.
    Chuwa EW; Yeo AW; Koong HN; Wong CY; Yong WS; Tan PH; Ho JT; Wong JS; Ho GH
    Breast J; 2009; 15(2):133-9. PubMed ID: 19292798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
    Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
    Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.
    Takahashi S; Thike AA; Koh VCY; Sasano H; Tan PH
    Virchows Arch; 2018 Sep; 473(3):275-283. PubMed ID: 30033510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of screening-detected ductal carcinoma in situ treated with wide excision alone.
    Fong J; Kurniawan ED; Rose AK; Mou A; Collins JP; Miller JA; Mann GB
    Ann Surg Oncol; 2011 Dec; 18(13):3778-84. PubMed ID: 21630124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
    Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
    Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does breast screening offer a survival benefit? A retrospective comparative study of oncological outcomes of screen-detected and symptomatic early stage breast cancer cases.
    Újhelyi M; Pukancsik D; Kelemen P; Kovács E; Kenessey I; Udvarhelyi N; Bak M; Kovács T; Mátrai Z
    Eur J Surg Oncol; 2016 Dec; 42(12):1814-1820. PubMed ID: 27424787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.
    Luiten JD; Voogd AC; Luiten EJT; Duijm LEM
    Breast Cancer Res Treat; 2017 Nov; 166(1):307-314. PubMed ID: 28748346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.